Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.42 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938882 | 0.79 | LATS1 (0.44) | HTR2CHTR2BHTR2AGSK3BRAD52 | |
| SCHEMBL1856410 | 0.76 | ADRB1 (0.43) | — | |
| SCHEMBL1852426 | 0.76 | HTR2C (0.34) | HTR2CHTR2BHTR2A | |
| SCHEMBL1851212 | 0.75 | HTR2C (0.40) | HTR2CHTR2BHTR2AGSK3BLATS1 | |
| SCHEMBL1853366 | 0.75 | HTR2C (0.43) | HTR2CHTR2BHTR2AGSK3BLATS1 | |
| SCHEMBL38663101 | 0.70 | GSK3B (0.52) | HTR2CHTR2BHTR2AGSK3BRAD52 | |
| SCHEMBL5461889 | 0.70 | GSK3B (0.52) | HTR2CHTR2BHTR2AGSK3BRAD52 | |
| SCHEMBL26669231 | 0.70 | GSK3B (0.52) | HTR2CHTR2BHTR2AGSK3BRAD52 | |
| SCHEMBL15416015 | 0.70 | MAP4K1 (0.37) | HTR2CHTR2BHTR2A | |
| SCHEMBL2877579 | 0.69 | ADRB1 (0.54) | HTR2CHTR2BHTR2ARAD52LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | claimed |
| EP-3953356-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | claimed |
| WO-2020207991-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-15 | — | — | WO | claimed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-3953356-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| WO-2020207991-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-10-22 | — | — | US | disclosed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | disclosed |
| EP-3386984-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-17 | — | — | EP | disclosed |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| WO-2015193168-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193169-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193167-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| EP-2935269-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2776445-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2014096423-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | HTR2C 3827/4885HTR2B 2732/4885HTR2A 4065/4885 |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2A | HTR2C 4017/4885HTR2B 3547/4885HTR2A 4450/4885 |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2B | HTR2C 2558/4885HTR2B 2809/4885HTR2A 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.